PI3K/Akt/mTOR inhibitors in breast cancer
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to Ⅲ trials involving inhibitors of the pathway have been or are being conducted in solid tumors...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
China Anti-Cancer Association
2015-12-01
|
| Edice: | Cancer Biology & Medicine |
| Témata: | |
| On-line přístup: | http://www.cancerbiomed.org/index.php/cocr/article/view/888 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|